3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Endocrine
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Breast Diseases
2
Unilateral Breast Neoplasms
1
Recurrence
1
Osteitis Deformans
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HR+/HER2- Breast Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Breast Neoplasms, Male
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Metastatic Breast Cancer
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
4
Gemcitabine
4
padeliporfin
3
napabucasin
3
Pemetrexed
3
Paclitaxel
3
Drug Therapy
3
Cisplatin
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ribociclib
2
palbociclib
2
Mitomycin
2
Gonadotropin-Releasing Hormone
2
Fluorouracil
2
Bevacizumab
2
Anastrozole
2
Albumin-Bound Paclitaxel
2
AZD9833
2
valrubicin
1
selinexor
1
pralsetinib
1
patritumab
1
palladium-bacteriopheophorbide
1
linifanib
1
ipatasertib
1
enfortumab vedotin
1
camrelizumab
1
atezolizumab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms by Site
×
ribociclib
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA